Additionally, it remains controversial how the 5α-reductase level changes with prostate cancer development and progression, as shown in a recent study by Wako et al. [42]: using semiquantitative immunohistochemical analysis, they found no significant change in SRD5A1 and SRD5A2 levels between localized prostate cancer samples and normal prostatic tissues. Here, SRD5A1 is linked to Familial prostate cancer.